Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $235 | $176 | $134 | $46 |
| % Growth | 34% | 31% | 193.9% | – |
| Cost of Goods Sold | $28 | $14 | $6 | $1 |
| Gross Profit | $207 | $161 | $128 | $45 |
| % Margin | 88% | 91.9% | 95.8% | 97.6% |
| R&D Expenses | $21 | $50 | $45 | $51 |
| G&A Expenses | $158 | $195 | $196 | $171 |
| SG&A Expenses | $172 | $195 | $196 | $171 |
| Sales & Mktg Exp. | $14 | $0 | $0 | $0 |
| Other Operating Expenses | $19 | $8 | -$2 | $3 |
| Operating Expenses | $212 | $253 | $240 | $225 |
| Operating Income | -$5 | -$92 | -$111 | -$181 |
| % Margin | -2% | -52.2% | -83.2% | -396.3% |
| Other Income/Exp. Net | $12 | $14 | $5 | $1 |
| Pre-Tax Income | $7 | -$77 | -$106 | -$180 |
| Tax Expense | $2 | $1 | $2 | $1 |
| Net Income | $6 | -$78 | -$108 | -$181 |
| % Margin | 2.4% | -44.5% | -80.7% | -396.8% |
| EPS | 0.04 | -0.54 | -0.76 | -1.4 |
| % Growth | 107.4% | 28.9% | 45.7% | – |
| EPS Diluted | 0.039 | -0.54 | -0.76 | -1.4 |
| Weighted Avg Shares Out | 143 | 143 | 142 | 129 |
| Weighted Avg Shares Out Dil | 146 | 143 | 142 | 129 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $17 | $5 | $1 |
| Interest Expense | $5 | $3 | $0 | $0 |
| Depreciation & Amortization | $19 | $12 | $3 | $3 |
| EBITDA | $32 | -$63 | -$104 | -$177 |
| % Margin | 13.5% | -35.9% | -77.3% | -389.1% |